General Information |
Summary |
This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD) |
Clinical trials phase |
Phase 1 |
Start date (estimated) |
2024-12-16 |
End date (estimated) |
2027-03-03 |
Clinical feature |
Label |
Duchenne muscular dystrophy |
Link |
http://purl.obolibrary.org/obo/DOID_11723 |
Description |
A muscular dystrophy that has_material_basis_in X-linked mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
NCT number |
NCT06692426 |
ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06692426 |
Other study identifiers |
|
Source weblink |
https://clinicaltrials.gov/study/NCT06692426 |
Regulatory body approval |
Name |
Food and Drug Administration (FDA) |
Country |
|
|
Public contact |
Email |
mdstemcell@umn.edu |
Public email |
mdstemcell@umn.edu |
First name |
Peter |
Last name |
Kang |
Phone |
+1 612-624-9452 |
|
Sponsors |
Masonic Cancer Center, University of Minnesota |
Collaborators |
|
Cells |
Recruitment |
Recruitment Status |
Not yet recruiting |
Estimated number of participants |
8 |